{"id":1018753,"date":"2026-11-09T09:44:36","date_gmt":"2026-11-09T14:44:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/onemednet-partners-to-combine-first-party-multimodal-clinical-data-with-comprehensive-patient-journey-ai-analytics-expanding-commercial-reach-through-13th-channel-partnership\/"},"modified":"2026-11-09T09:44:36","modified_gmt":"2026-11-09T14:44:36","slug":"onemednet-partners-to-combine-first-party-multimodal-clinical-data-with-comprehensive-patient-journey-ai-analytics-expanding-commercial-reach-through-13th-channel-partnership","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onemednet-partners-to-combine-first-party-multimodal-clinical-data-with-comprehensive-patient-journey-ai-analytics-expanding-commercial-reach-through-13th-channel-partnership\/","title":{"rendered":"OneMedNet Partners to Combine First-Party Multimodal Clinical Data with Comprehensive Patient-Journey AI Analytics, Expanding Commercial Reach Through 13th Channel Partnership"},"content":{"rendered":"

\nAgreement enables an AI-powered healthcare intelligence company to re-sell OneMedNet\u2019s first-party, direct-from-source multimodal Real-World Data in combination with its own longitudinal patient-journey assets, which include broad claims, pharmacy, and encounter coverage
\n<\/h2>\n
\n

MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (\u201cOneMedNet,\u201d the \u201cCompany,\u201d \u201cwe,\u201d \u201cus\u201d or \u201cour\u201d), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 13th channel partner agreement. Under the agreement, an AI-powered healthcare intelligence company will re-sell OneMedNet\u2019s U.S.-sourced, de-identified multimodal clinical data in combination with its own comprehensive real-world patient journey assets. As part of the Company\u2019s channel strategy, this is OneMedNet\u2019s third AI-focused channel partner.<\/p>\n

This partnership continues the Company\u2019s deliberate strategy of extending commercial reach through established distribution partners in AI and pharmaceutical research while retaining direct control of data sourcing, curation, and de-identification. The agreement follows recent channel agreements, including our partnership with a global provider of pharmaceutical intelligence and data solutions and another with Mediplexus for distribution into Korea and the broader Asia Pacific region.<\/p>\n

This new collaboration is designed to give foundational AI and other customers a more complete view of the patient journey by pairing OneMedNet\u2019s first-party, direct-from-source multimodal clinical data spanning longitudinal clinical records including physician notes, labs, imaging, and reports, from a live network of more than 2,300 healthcare partner sites with the partner\u2019s broad coverage of claims, pharmacy, encounters, and related administrative data across hundreds of millions of U.S. patient journeys. The combined offering is intended to support use cases healthcare AI model training, clinical development, real-world evidence generation, market access, health economics and outcomes research (HEOR) that benefit from both administrative breadth and clinical depth. The partnership is already delivering commercial momentum, adding approximately 25% to OneMedNet\u2019s sales funnel.<\/p>\n

OneMedNet\u2019s iRWD\u2122 network currently encompasses more than 90 million patient journeys and 270 million studies. Data is sourced directly from healthcare providers rather than intermediaries or secondary markets and is de-identified at the source to regulatory-grade standards.<\/p>\n

\u201cOur channel partners continue to choose OneMedNet because the data comes straight from the source,\u201d said Aaron Green, President & CEO of OneMedNet. \u201cFirst-party, direct-from-source multimodal data gives partners the clinical depth and provenance their customers need. Combining that with a leading platform\u2019s broad patient-journey coverage creates a differentiated offering that neither dataset can deliver alone.\u201d<\/p>\n

\n Partnership Highlights<\/strong>\n <\/p>\n